¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"platelet glycoprotein gpib-ix complex"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • ethmomaxillary complex
    ¹úÁýÀ§ÅλÀº¹ÇÕü, »ç°ñ»ó¾Çº¹ÇÕü
  • father complex
    ¾Æ¹öÁöÄÞÇ÷º½º
  • factor IX complex
    Á¦9ÀÎÀÚº¹ÇÕü
  • Golgi complex
    °ñÁöº¹ÇÕü
  • histocompatibility complex
    Á¶Á÷ÀûÇÕ¼ºº¹ÇÕü
  • HLA complex
    HLAº¹ÇÕü
  • human leukocyte antigen complex
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕü
  • human leukocyte antigen complex gene
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕüÀ¯ÀüÀÚ
  • immune complex
    ¸é¿ªº¹ÇÕü
  • immune complex mediated hypersensitivity
    ¸é¿ªº¹ÇÕü¸Å°³°ú¹Î¼º
  • immune-complex disease
    ¸é¿ªº¹ÇÕüº´
  • inferiority complex
    ¿­µîÄÞÇ÷º½º
  • junctional complex
    ÀÌÀ½ºÎº¹ÇÕü
  • major histocompatibility complex
    ÁÖÁ¶Á÷ÀûÇÕº¹ÇÕü
  • minor histocompatibility complex
    ºÎÁ¶Á÷ÀûÇÕº¹ÇÕü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Golgi¡¯s complex
    °ñÁöº¹ÇÕü
  • human leukocyte antigen complex
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕü
  • immune complex
    ¸é¿ªº¹ÇÕü
  • inferiority complex
    ¿­µîÄÞÇ÷º½º, ¿­µî°¨
  • junctional complex
    ¿¬Á¢º¹ÇÕü
  • major histocompatibility complex
    ÁÖÁ¶Á÷ÀûÇÕº¹ÇÕü
  • Merkel cell-neurite complex
    Ã˰¢¼¼Æ÷½Å°æµ¹±âº¹ÇÕü
  • minor histocompatibility complex
    ºÎÁ¶Á÷ÀûÇÕº¹ÇÕü
  • mother complex
    ¾î¸Ó´ÏÄÞÇ÷º½º
  • mother-infant complex
    ¸ðÀÚÄÞÇÁ·º½º
  • primary complex
    Ãʱ⺯ȭ±º, ¿ø¹ßº¹ÇÕü
  • primary inoculation complex
    ¿ø¹ßÁ¢Á¾º¹ÇÕü
  • synaptonemal complex
    ¿¬Á¢½Çº¹ÇÕü
  • immune-complex disease
    ¸é¿ªº¹ÇÕüº´
  • human leukocyte antigen complex gene
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕüÀ¯ÀüÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • prothrombin complex concentrates
    ÇÁ·ÎÆ®·Òºó º¹ÇÕ ³óÃà(¹°)
  • Grey platelet syndrome
    ±×·¹ÀÌÇ÷¼ÒÆÇÁõÈıº
  • MPV => mean platelet volume
    Æò±ÕÇ÷¼ÒÆÇ¿ëÀû
  • PAF =platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ.
  • PAF= platelet activating factor
    Ç÷¼ÒÆÇ Ȱ¼ºÀÎÀÚ.
  • granulocyte-platelet-lymphocyte antigens
    °ú¸³±¸Ç÷¼ÒÆÇ¸²ÇÁ±¸Ç׿ø
  • hellp(hemolysis, elevated liver enzymes, low platelet),heliminths
    À±Ãæ(ëÌõù)
  • hemorrhagic diathesis,defective platelet function
    Ç÷¼ÒÆÇ±â´É°á¼Õ(úìá³÷ùѦÒöÌÀáß)
  • platelet
    Ç÷¼ÒÆÇ(úìá³÷ù).
  • platelet
    Ç÷¼ÒÆÇ(úìá³÷ù)
  • platelet
    Ç÷¼ÒÆÇ
  • platelet activating factor
    Ç÷¼ÒÆÇ Ȱ¼º ÀÎÀÚ
  • platelet adhesion
    Ç÷¼ÒÆÇºÎÂø
  • platelet agglutination
    Ç÷¼ÒÆÇÀÀÁý
  • platelet aggregation
    Ç÷¼ÒÆÇÀÀÁý
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • platelet transfusion
    Ç÷¼ÒÆÇ¼öÇ÷
  • platelet transfusion
    Ç÷¼ÒÆÇ¼öÇ÷(¡­âÃúì).
  • platelet,adhesion
    À¯Âø(ë¨ó·),ºÎÂø(ݾó·),Á¢Âø(ïÈó·)
  • platelet,aggregation
    ÀÀÁý(ëêó¢), ÀÀ±«(ëêÎÔ)
  • platelet-activating factor (PAF)
    Ç÷¼ÒÆÇ Ȱ¼ºÈ­ÀÎÀÚ
  • platelet-activating factor (paf)
    Ç÷¼ÒÆÇȰ¼ºÈ­ÀÎÀÚ(úìá³÷ùüÀàõûùì×í­)
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡ Áõ½ÄÀÎÀÚ
  • platelet-derived growth factor(PDGF)
    Ç÷¼ÒÆÇ À¯·¡ ¼ºÀå ÀÎÀÚ
  • platelet-derived growth factor(pdgf)
    ÆÇ-À¯µµ¼ºÀåÀÎÀÚ(úìá³÷ù-ë¯Óôà÷íþì×í­)
  • platelet-specific antigens
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • platelet-type
    Ç÷¼ÒÆÇÇü(û¡)
  • therapeutic platelet-leukapheresis
    Ä¡·áÀû Ç÷¼ÒÆÇ¹éÇ÷±¸¼ººÐäÁý¼ú
  • thrombocyte [blood platelet]
    Ç÷¼ÒÆÇ
  • activated complex
    Ȱ¼ºº¹ÇÕ, Ȱ¼ºº¹ÇÕ¹°
  • acyl-plasminogen streptokinase activator complex
    ¾Æ½Ç-Çø®Áî¹Ì³ë°Õ½ºÆ®·¾ÅäŰ³ªÁ¦È°¼ºÁ¦º¹ÇÕü
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • mixed complex
    È¥¼ºº¹ÇÕ¹°(ûèà÷ÜÜùêÚª)
  • mononuclear complex
    ´ÜÇÙº¹ÇÕ¹°(Ó¤ú·ÜÜùêÚª)
  • multienzyme complex
    ´ÙÈ¿¼Òº¹ÇÕ¹°(Òýý£áÈÜÜùêÚª)
  • NADH-dehydrogenase complex
    NADH-µðÇÏÀ̵å·ÎÀú³×À̽º º¹ÇÕü(ÜÜùêô÷)
  • nonproductive complex
    ºñ»ý»ê º¹ÇÕü(Þªßæß§ÜÜùêô÷)
  • open-promoter complex
    ¿­¸°ÇÁ·Î¸ðÅÍ º¹ÇÕü(ÜÜùêô÷)
  • polynuclear complex
    ´ÙÇÙ º¹ÇÕ¹°(Òýú·ÜÜùêÚª)
  • productive complex
    »ý»ê º¹ÇÕü(ßæß§ÜÜùêô÷)
  • pyruvate dehydrogenase complex
    ÆÄÀÌ·çºê»ê(ß«) µðÇÏÀ̵å·ÎÀú³×À̽º º¹ÇÕü(ÜÜùêô÷)
  • rapid start complex
    ±ÞÀÛ º¹ÇÕ¹°(ÐáíÂÜÜùêÚª)
  • redox complex
    ·¹µ¶½º È¥ÇÕ¹°(ûèùêÚª)
  • relaxation complex
    ÀÌ¿Ï º¹ÇÕü(ì¬èÐÜÜùêô÷)
  • respiratory complex
    È£Èí º¹ÇÕü(ÜÜùêô÷)
  • respiratory enzyme complex
    È£Èí È¿¼Ò º¹ÇÕü(ÜÜùêô÷)
  • substrate-bridge complex
    ±âÁú°¡±³ º¹ÇÕü(ÐñòõÊ­ÎéÜÜùêô÷)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
HCG, hCG Human Chorionic Gonadotropin; »ç¶÷À¶¸ð¼º¼º¼±ÀÚ±ØÈ£¸£¸ó
  1. Placental Glycoprotein Hormone
&nbs...
MAG Myelin Associated Glycoprotein
SP1 pregnancy-specific ¥â1-glycoprotein
AAG 3-alkaladenine deoxyribonucleic acid glycosylase; allergic angiitis and granulomatosis; alpha-1-acid...
AGP acid glycoprotein; agar gel precipitation; azurophil granule protein
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
MAIPA Monoclonal Antibody-specific Immobilisation of Platelet Antigens
P- Platelet
PLT Platelet
PAR Platelet Aggregate Ratio
PBP Platelet Basic Protein
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • protein-drug complex
    ´Ü¹é-¾à¹° º¹ÇÕü
  • receptor complex
    ¼ö¿ëü º¹ÇÕü, ¼ö¿ë±â º¹ÇÕü
  • self-associated rheumatoid factor complex

    self-care (ÀÚ°¡ Ä¡·á

  • tuberculous primary complex
    °áÇÙ¼º ÀÏÂ÷ º¹ÇÕü
  • VB complex
    VB º¹ÇÕü
  • vesitibular nuclear complex
    ÀüÁ¤½Å°æ ÇÙ
  • vitamin B complex
    ºñŸ¹ÎB º¹ÇÕü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
platelet cofactor II <chemical> Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, ixa, forms a complex with factor viii and calcium on platelet factor 3 to activate factor x to xa. Deficiency of factor ix results in christmas disease (haemophilia b).
Chemical name: Blood-coagulation factor IX
(12 Dec 1998)
platelet count <haematology> The number of platelets per cubic millimetre of blood. The normal range is 150,000-400,000 platelets per cubic mm. Platelet counts under 10,000 per cubic millimetre place the patient at risk for spontaneous haemorrhage. Platelets are produced in the bone marrow in increased quantities in response to stress.
(27 Sep 1997)
platelet-derived growth factor <growth factor> The major mitogen in serum for growth in culture of cells of connective tissue origin. It consists of 2 different but homologous polypeptides A and B (~30,000 D) linked by disulphide bonds. Believed to play a role in wound healing.
It is carried in the alpha-granules of platelets and is released when platelets adhere to traumatised tissues. Connective tissue cells near the traumatised region respond by initiating the process of replication.
The B chain is almost identical in sequence to p28sis, the transforming protein of simian sarcoma virus, that can transform only those cells that express receptors for platelet derived growth factor, suggesting that transformation is caused by autocrine stimulation. The receptor is a tyrosine kinase.
Acronym: PDGF
(12 Dec 1998)
platelet endothelial cell activated protease <enzyme> Degrades casein and fibrinogen; secreted by endothelial cells and activated in the extracellular medium by platelets; not inhibited by serine protease inhibitors, metalloproteinase inhibitors, or cystein protease inhibitors; pH optimum 7.5
Registry number: EC 3.4.99.-
Synonym: pecap
(26 Jun 1999)
platelet factor 3 <haematology> Phospholipid associated with the platelet plasma membrane that contributes to the blood clotting cascade by forming a complex (thromboplastin) with other plasma proteins and activating prothrombin.
(31 Dec 1997)
platelet factor 4 <haematology> Platelet released protein that promotes blood clotting by neutralising heparin.
(31 Dec 1997)
platelet function disorders <haematology> Platelet function can be affected by a number of different disease processes including polycythaemia vera, leukaemia, myelofibrosis, renal failure, multiple myeloma and some medications (for example penicillins, salicylates, phenothiazines).
Disturbed blood clotting can be manifested by: easy bruising, bleeding gums, nosebleeds, abnormal vaginal bleeding, rectal bleeding, skin rash, vomiting blood, coughing up blood or blood in the urine. A measure of bleeding time and coagulation profile will be part of the evaluation.
(31 Dec 1997)
platelet membrane glycoproteins Surface glycoproteins on platelets which have a key role in haemostasis and thrombosis such as platelet adhesion and aggregation. Many of these are receptors.
(12 Dec 1998)
platelet storage pool deficiency A group of disorders characterised by a decrease or lack of platelet dense bodies in which the releasable pool of adenine nucleotides and 5ht are normally stored.
(12 Dec 1998)
platelet thrombosis Thrombosis due to an abnormal accumulation of platelets.
(05 Mar 2000)
platelet tissue factor <haematology> Traditional name for substance in plasma that converts prothrombin to thrombin. Now known not to be a single substance. (See thrombin).
(18 Nov 1997)
platelet transfusion The transfer of blood platelets from a donor to a recipient or reinfusion to the donor.
(12 Dec 1998)
low affinity platelet factor IV Cytokine, produced from platelet basic protein, that acts as a growth factor.
(18 Nov 1997)
low platelet count <haematology> An abnormally low platelet count. Normal platelet counts are 150,000-400,000 per cubic millimetre.
Those with low platelet counts may exhibit haematuria, haematemesis, easy bruising, bleeding gums, melena (blood in stools), prolonged menses or nosebleeds. Spontaneous intracranial haemorrhage can occur with platelet counts of 10-15,000 (or less).
(27 Sep 1997)
aberrant complex An anomalous electrocardiographic complex, more specifically an abnormal ventricular complex caused by abnormal intraventricular conduction of a supraventricular impulse.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á